Compare Nasdaq100 ETF (QQQ) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq100 ETF vs TransMedics Group Inc — how do they compare? Nasdaq100 ETF trades at $714.45, while TransMedics Group Inc trades at $86.4 (market cap $3.00B). The key difference: Nasdaq100 ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| QQQ | TMDX | |
|---|---|---|
52-Week High | $746.16 | $150.42 |
52-Week Low | $558.34 | $61.99 |
Market Cap | — | $3.00B |
Sector | — | Technology |
Enterprise Value | — | $3.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQ trades at $718.36, down slightly by 0.08% on the day, with a bullish technical outlook from moving averages and neutral oscillators. Support levels are at $715 and $712, with resistance at $722 and $725. Analyst sentiment is split evenly between buy and sell recommendations, reflecting uncertainty amid mixed news coverage.
The ETF's outlook is supported by strong historical performance and growth exposure, but risks include fee competitiveness and market volatility. Investors should weigh the divided analyst consensus against the fund's track record in technology and growth sectors.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
